Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Microbix Biosystms ( (TSE:MBX) ).
Microbix Biosystems has commercialized its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, for use in its QAPs quality assessment line and for sale at commercial scale to test manufacturers, marking the first market-ready output from its recombinant antigen development program launched in 2025. By adding internally produced synthetic antigens to its long-established native antigen capabilities, the company aims to strengthen supply-chain security, cost control, and technical flexibility for quality assessment materials used in proficiency testing and clinical lab quality management, particularly for enduring SARS-CoV-2 testing needs, where related QAPs already represent a meaningful share of its C$5.6 million fiscal 2025 QAPs revenue.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that develops and manufactures proprietary biological products for the global diagnostics industry, including viral antigens for immunoassays, quality assessment products (QAPs), and QUANTDx reference materials used in clinical lab proficiency testing, assay development, and diagnostic workflow quality control. With more than 120 employees and annual revenues of C$18.6 million in fiscal 2025, its products support about 100 diagnostics makers and are distributed in over 30 countries, backed by multiple international regulatory accreditations, while the company also advances other proprietary assets such as the Kinlytic urokinase thrombolytic drug and diagnostic testing reagents like DxTM.
Average Trading Volume: 50,012
Technical Sentiment Signal: Sell
Current Market Cap: C$33.36M
See more insights into MBX stock on TipRanks’ Stock Analysis page.